Search - tctmd.com

Displaying 101 - 120 of 232

Sort: Relevancy | Date

DOAC Use Increasing in Patients With Bioprosthetic Heart Valves

News Conference News CRT 2021

DOAC Use Increasing in Patients With Bioprosthetic Heart Valves

March 08, 2021

High Burden of Post-CABG A-fib After Hospital Discharge: SEARCH-AF

News Conference News AHA 2020

High Burden of Post-CABG A-fib After Hospital Discharge: SEARCH-AF

Michael O'Riordan

November 16, 2020

Rivaroxaban an Option for Patients with Bioprosthetic Mitral Valves and A-fib

News Conference News AHA 2020

Rivaroxaban an Option for Patients with Bioprosthetic Mitral Valves and A-fib

November 14, 2020

Valve Disease Plus COVID-19 Often a Lethal Combination, Registry Shows

News Conference News TCT 2020

Valve Disease Plus COVID-19 Often a Lethal Combination, Registry Shows

October 14, 2020

No Reperfusion Benefit From Crushed Prasugrel Prior to PCI: COMPARE CRUSH

News Conference News TCT 2020

No Reperfusion Benefit From Crushed Prasugrel Prior to PCI: COMPARE CRUSH

October 14, 2020

Chinese Data Back Anticoagulants to Prevent COVID-19 Thromboembolism

News Conference News ESC 2020

Chinese Data Back Anticoagulants to Prevent COVID-19 Thromboembolism

September 04, 2020

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

News Conference News ESC 2020

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

September 03, 2020

Got Mail? Letter-Based Intervention Doesn’t Boost OAC Initiation for A-fib

News Conference News ESC 2020

Got Mail? Letter-Based Intervention Doesn’t Boost OAC Initiation for A-fib

September 03, 2020

Updated ESC A-fib Guidance Proposes New Path for Diagnosis, Classification, and Care

News Conference News ESC 2020

Updated ESC A-fib Guidance Proposes New Path for Diagnosis, Classification, and Care

August 30, 2020

News Conference News ESC 2020

Go With Aspirin Alone After TAVR When Anticoagulation Isn’t Needed: POPular TAVI

August 30, 2020

Antithrombotics After PFO Closure: Much to Discuss, Little Data to Inform

News Conference News TVT 2020

Antithrombotics After PFO Closure: Much to Discuss, Little Data to Inform

Yael L. Maxwell

June 26, 2020

Stroke in TAVR Full Impact of Embolic Devices, Anticoagulants, Technique Remain Unclear

News Conference News TVT 2020

Stroke in TAVR: Full Impact of Embolic Devices, Anticoagulants, Technique Remain Unclear

June 25, 2020

Reduced Leaflet Motion After TAVR: No Link to Impaired Hemodynamics, Events

News Conference News TVT 2020

Reduced Leaflet Motion After TAVR: No Link to Impaired Hemodynamics, Events

Michael O'Riordan

June 23, 2020

Sapien 3 in Intermediate Risk: Death or Stroke Similar to SAVR at 5 Years

News Conference News TVT 2020

Sapien 3 in Intermediate Risk: Death or Stroke Similar to SAVR at 5 Years

Michael O'Riordan

June 22, 2020

PINNACLE FLX: New-Generation Watchman Has High Closure Rates, Good Safety

News Conference News HRS 2020

PINNACLE FLX: New-Generation Watchman Has High Closure Rates, Good Safety

May 15, 2020

Edoxaban May Be Alternative to Warfarin After Surgical Valve Implantation or Repair

News Conference News ACC 2020

Edoxaban May Be Alternative to Warfarin After Surgical Valve Implantation or Repair

April 07, 2020

LAAO Registry: Safety of Watchman Looks Good in First Years of Rollout

News Conference News ACC 2020

LAAO Registry: Safety of Watchman Looks Good in First Years of Rollout

April 06, 2020

Aspirin Okay for Up to 30 Days

News Conference News ACC 2020

Aspirin Okay for Up to 30 Days in A-fib Patients After ACS or PCI: AUGUSTUS

April 03, 2020

PRONOMOS: Rivaroxaban Beats Enoxaparin for Preventing VTE After Orthopedic Surgery

News Conference News ACC 2020

PRONOMOS: Rivaroxaban Beats Enoxaparin for Preventing VTE After Orthopedic Surgery

Yael L. Maxwell

March 31, 2020

PARTNER 3: TAVR Now Noninferior to Surgery at 2 Years in Low-Risk Patients

News Conference News ACC 2020

PARTNER 3: TAVR Now Noninferior to Surgery at 2 Years in Low-Risk Patients

Yael L. Maxwell

March 29, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.